Metabolic Dysfunction-Associated Fatty Liver Disease, Statins, and Atherosclerotic Cardiovascular Disease Reply

被引：0
|
作者：
Yeoh, Aaron [1 ]
Cheung, Ramsey [1 ,2 ]
Ahmed, Aijaz [1 ]
Chitnis, Amit S. [3 ]
Do, Albert [4 ]
Wong, Robert J. [1 ,2 ]
机构：
[1] Stanford, Dept Med, Div Gastroenterol, Palo Alto, CA 94304 USA
[2] Vet Affairs Palo Alto Hlth Care Syst, Gastroenterol Sect, Palo Alto, CA USA
[3] Alameda Cty Publ Hlth Dept, Div Communicable Dis Control & Prevent, TB Sect, San Leandro, CA USA
[4] Yale, Dept Med, Div Digest Dis, New Haven, CT USA
来源：
AMERICAN JOURNAL OF MEDICINE | 2024年 / 137卷 / 01期
关键词：
D O I：
10.1016/j.amjmed.2023.08.024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E15 / E15
页数：1
相关论文
共 50 条
  • [31] The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
    Goya, Takeshi
    Imoto, Koji
    Tashiro, Shigeki
    Aoyagi, Tomomi
    Takahashi, Motoi
    Kurokawa, Miho
    Suzuki, Hideo
    Tanaka, Masatake
    Kato, Masaki
    Kohjima, Motoyuki
    Ogawa, Yoshihiro
    GASTROENTEROLOGY INSIGHTS, 2022, 13 (01) : 20 - 26
  • [32] Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice?
    Gambardella, Maria Luisa
    Abenavoli, Ludovico
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2025, 86 (02)
  • [33] Disease severity assessment of metabolic dysfunction-associated fatty liver disease in Taiwan
    Huang, Jee-Fu
    Tsai, Pei-Chien
    Huang, Ching-I
    Yeh, Ming-Lun
    Huang, Chung-Feng
    Dai, Chia-Yen
    Yu, Ming-Lung
    JOURNAL OF HEPATOLOGY, 2022, 77 : S458 - S459
  • [34] Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
    Alam, Shahinul
    Fahim, Shah Mohammad
    WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (10) : 1203 - 1207
  • [35] Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
    Shahinul Alam
    Shah Mohammad Fahim
    World Journal of Hepatology, 2021, 13 (10) : 1203 - 1207
  • [36] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    Han, A. Lum
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):
  • [37] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    A Lum Han
    Diabetology & Metabolic Syndrome, 14
  • [38] FERRITIN IS ASSOCIATED WITH INCREASED MORTALITY, PROGRESSION TO CIRRHOSIS, AND DEVELOPMENT OF CARDIOVASCULAR DISEASE IN METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
    Suresh, Deepika
    Miller, Matthew
    Wijarnpreecha, Karn
    Chen, Vincent
    HEPATOLOGY, 2022, 76 : S714 - S715
  • [39] Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang
    Guo, Yanbo
    Yang, Jing
    Ma, Rulin
    Zhang, Xianghui
    Guo, Heng
    He, Jia
    Wang, Xinping
    Cao, Boyu
    Maimaitijiang, Remina
    Li, Yu
    Peng, Xinyu
    Zhang, Shijie
    Guo, Shuxia
    NUTRIENTS, 2022, 14 (12)
  • [40] Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches
    Dongiovanni, Paola
    Paolini, Erika
    Corsini, Alberto
    Sirtori, Cesare R.
    Ruscica, Massimiliano
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (07)
12345